Bill Lundberg, MD

Bill Lundberg, MD is a medical oncologist with more than two decades of experience managing and leading biotechnology research and development. Bill is President and CEO at Merus, a clinical-stage oncology company developing innovative, full-length multispecific antibodies. Prior to joining Merus, he served as Chief Scientific Officer at CRISPR Therapeutics, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR’s first CRISPR-based product from inception to regulatory filing for clinical trials. Bill was previously Director and Chief Medical Officer of Taligen Therapeutics and Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he oversaw R&D from discovery through early clinical development. Prior to this, he held roles of increasing responsibility in drug development and medical affairs at Xanthus (acquired by Antisoma), Wyeth (now Pfizer), and Genzyme. Bill received an MD from Stanford University School of Medicine, an MBA from Isenberg School of Management and a BS from Massachusetts Institute of Technology. He completed postdoctoral training at the Whitehead Institute/MIT and clinical training in medicine and medical oncology from Harvard and the Dana-Farber Cancer Institute.